Your browser doesn't support javascript.
loading
PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies.
Salem, Ahmed Ebada; Shah, Harsh R; Covington, Matthew F; Koppula, Bhasker R; Fine, Gabriel C; Wiggins, Richard H; Hoffman, John M; Morton, Kathryn A.
Afiliação
  • Salem AE; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
  • Shah HR; Department of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.
  • Covington MF; Department of Medicine, Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA.
  • Koppula BR; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
  • Fine GC; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
  • Wiggins RH; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
  • Hoffman JM; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
  • Morton KA; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
Cancers (Basel) ; 14(23)2022 Nov 30.
Article em En | MEDLINE | ID: mdl-36497423
PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and evaluation of suspected recurrence. The goal of this 6-part series of review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. In the first article of this series, hematologic malignancies are addressed. The classification of these malignancies will be outlined, with the disclaimer that the classification of lymphomas is constantly evolving. Critical applications, potential pitfalls, and nuances of PET-CT imaging in hematologic malignancies and imaging features of the major categories of these tumors are addressed. Issues of clinical importance that must be reported by the imaging professionals are outlined. The focus of this article is on [18F] fluorodeoxyglucose (FDG), rather that research tracers or those requiring a local cyclotron. This information will serve as a resource for the appropriate role and limitations of PET-CT in the clinical management of patients with hematological malignancy for health care professionals caring for adult patients with hematologic malignancies. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article